IL1B and lung adenocarcinoma: We incubated HBEC-3KT and HSAEC-1KT, as well as the 7 lung adenocarcinoma cells of varying driver mutations (Table 1) with 5 ng/mL IL-1β for 48 h and performed RT-qPCR, Western blotting, and cell viability assays to determine their response to IL-1β (Fig. 1B).